Stockpolly
Search
MAIA · AMEX · Biotechnology

MAIA Biotechnology (MAIA)

Developing ateganosine, a telomere-targeting treatment for later-line lung cancer.

$1.37
Pre-market−0.01 (−1.08%)
At close$1.39(+6.54%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
64445559478
Research & development42233336246
32222223233
General & administrative32222223233
Operating income−6−4−4−4−5−5−5−9−4−7−8
0−4−511100111
Interest income00000000000
Interest expense00000000000
Other non-operating income000−1−1−100−1−1−1
Income before tax−6−8−9−3−4−5−5−9−4−6−8
Income tax expense00000000000
Net income from continuing operations−6−8−9−3−4−5−5−9−4−6−8
Net income−6−8−9−3−4−5−5−9−4−6−8
EPS, basic−$0.37−$0.46−$0.40−$0.11−$0.14−$0.16−$0.18−$0.27−$0.09−$0.14−$0.13
EPS, diluted−$0.37−$0.46−$0.40−$0.11−$0.14−$0.16−$0.18−$0.27−$0.09−$0.14−$0.13
Weighted average shares, basic1718222426283033323261
Weighted average shares, diluted1718222426283033323261
EBITDA−6−4−4−31−5−50−4−6−8
Depreciation & amortization00005009000
EBIT−6−4−4−3−4−5−5−9−4−6−8